SubHero Banner

Nucala® (mepolizumab) – New formulation approval

June 6, 2019 - GlaxoSmithKline announced the FDA approval of Nucala (mepolizumab) single-dose prefilled autoinjector and single-dose prefilled syringe, for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype; and treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).

Download PDF